Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag

PURPOSE: This study is aimed at investigating the clinical safety and effectiveness of anlotinib combined with immune checkpoint inhibitors (ICIs) in the treatment of non-small-cell lung cancer (NSCLC). METHODS: We selected 68 NSCLC patients treated at the Tumor Hospital Affiliated to Nantong Univer...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Linghui, Chen, Xi, Ding, Lingchi, Zhang, Xuedong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586774/
https://www.ncbi.nlm.nih.gov/pubmed/36276277
http://dx.doi.org/10.1155/2022/1530875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586774/
https://www.ncbi.nlm.nih.gov/pubmed/36276277
http://dx.doi.org/10.1155/2022/1530875

Ejemplares similares